{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:50:07Z","timestamp":1791467407244,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Korea Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22213MFDS421"],"award-info":[{"award-number":["22213MFDS421"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Korea Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2025-02213409"],"award-info":[{"award-number":["RS-2025-02213409"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128235","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T22:03:05Z","timestamp":1768600985000},"page":"128235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay"],"prefix":"10.1016","volume":"75","author":[{"given":"Ohseok","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wooyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyebin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128235_bb0005","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/infdis\/jiy717","article-title":"Comparing influenza vaccine types: the path toward improved influenza vaccine strategies","volume":"220","author":"Flannery","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128235_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/irv.12543","article-title":"Standardisation of inactivated influenza vaccines-learning from history","volume":"12","author":"Wood","year":"2018","journal-title":"Influ Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128235_bb0015","article-title":"A rapid virus-free method for producing influenza HA immunogen needed for preparation of influenza vaccine potency antisera reagents","volume":"18","author":"Odin","year":"2024","journal-title":"Influ Other Respir Viruses."},{"key":"10.1016\/j.vaccine.2026.128235_bb0020","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.vaccine.2011.11.101","article-title":"Generation of recombinant pandemic H1N1 influenza virus with the HA cleavable by bromelain and identification of the residues influencing HA bromelain cleavage","volume":"30","author":"Wang","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128235_bb0025","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/289366a0","article-title":"Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 \u00c5 resolution","volume":"289","author":"Wilson","year":"1981","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128235_bb0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1099\/jgv.0.000457","article-title":"Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza a (H3N2) vaccine viruses","volume":"97","author":"Parker","year":"2016","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2026.128235_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/srep15279","article-title":"H3N2 mismatch of 2014\u201315 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps","volume":"5","author":"Xie","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128235_bb0040","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2020.1721223","article-title":"Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products","volume":"16","author":"Lai","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128235_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128235_bb0050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.virusres.2015.04.005","article-title":"Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines","volume":"204","author":"Shin","year":"2015","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.128235_bb0055","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-018-0079-z","article-title":"Cell culture-derived influenza vaccines in the severe 2017\u20132018 epidemic season: a step towards improved influenza vaccine effectiveness","volume":"3","author":"Barr","year":"2018","journal-title":"npj Vaccin"},{"key":"10.1016\/j.vaccine.2026.128235_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.7774\/cevr.2020.9.1.56","article-title":"Comparison of antigenic mutation during egg and cell passage cultivation of H3N2 influenza virus","volume":"9","author":"Park","year":"2020","journal-title":"Clin Exp Vaccin Res"},{"key":"10.1016\/j.vaccine.2026.128235_bb0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/vaccines11010052","article-title":"Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness","volume":"11","author":"Rockman","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.128235_bb0070","doi-asserted-by":"crossref","unstructured":"Robertson JS. Clinical influenza virus and the embryonated hen's egg rev med virol. 1993;3:97\u2013106. Doi: https:\/\/doi.org\/10.1002\/rmv.1980030206.","DOI":"10.1002\/rmv.1980030206"},{"key":"10.1016\/j.vaccine.2026.128235_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/infdis\/160.2.191","article-title":"Efficacy of inactivated influenza a virus (H3N2) vaccines grown in mammalian cells or embryonated eggs","volume":"160","author":"Katz","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128235_bb0080","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1016\/j.vaccine.2015.07.104","article-title":"Critical review of current and emerging quantification methods for the development of influenza vaccine candidates","volume":"33","author":"Manceur","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128235_bb0085","article-title":"Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories. World health organ tech rep S. World health","volume":"No. 979. Annex 5","author":"World Health Organization","year":"2012","journal-title":"Organization"},{"key":"10.1016\/j.vaccine.2026.128235_bb0090","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1080\/21645515.2018.1460297","article-title":"Cell culture-derived flu vaccine: present and future","volume":"14","author":"P\u00e9rez Rubio","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128235_bb0095","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2026.128235_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza a virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128235_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1147028","article-title":"An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines","volume":"14","author":"Bodle","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128235_bb0110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/vaccines12060596","article-title":"Analysing the potency of a seasonal influenza vaccine using reference antisera from heterologous strains","volume":"12","author":"Wadey","year":"2024","journal-title":"Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:50:02Z","timestamp":1772553002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":22,"alternative-id":["S0264410X26000423"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128235","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"128235"}}